| Autor: |
Pedersen ESL; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland., Mallet MC; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland.; Graduate School for Health Sciences, University of Bern, 3012 Bern, Switzerland., Lam YT; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland., Bellu S; Associazione Italiana Discinesia Ciliare Primaria Sindrome di Kartagener Onlus, 70124 Bari, Italy., Cizeau I; Association ADCP, 42218 Saint-Étienne, France., Copeland F; PCD Support UK, London MK18 9DX, UK., Fernandez TL; Asociación Española de Pacientes con Discinesia Ciliar Primaria, Santo Ángel 30151, Philippines., Manion M; PCD Foundation, Minneapolis, MN 55420, USA., Harris AL; Primary Ciliary Dyskinesia Centre, NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK., Lucas JS; Primary Ciliary Dyskinesia Centre, NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.; Faculty of Medicine, School of Clinical and Experimental Medicine, University of Southampton, Southampton SO17 1BJ, UK., Santamaria F; Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy., Goutaki M; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland.; Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland., Kuehni CE; Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland.; Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland., Covid-Pcd Patient Advisory Group |
| Abstrakt: |
Primary ciliary dyskinesia (PCD) is a rare genetic disease that causes recurrent respiratory infections. People with PCD may be at higher risk of severe coronavirus disease 2019 (COVID-19), and therefore vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important. We studied vaccination willingness, speed of vaccination uptake, side effects, and changes in social contact behaviour after vaccination in people with PCD. We used data from COVID-PCD, an international participatory cohort study. A COVID-19 vaccination questionnaire was emailed to participants in May 2021 and 423 participants from 31 countries replied (median age: 30 years, range 1-85 years; 261 (62%) female). Vaccination uptake and willingness were high, with 273 of 287 adults (96%) being vaccinated or willing to be in June 2021; only 4% were hesitant. The most common reason for hesitancy was fear of side effects, reported by 88%. Mild side effects were common, but no participant reported severe side effects. Half of the participants changed their social behaviour after vaccination by seeing friends and family more often. The high vaccination willingness in the study population might reflect the extraordinary effort taken by PCD support groups to inform people about COVID-19 vaccination. Clear and specific information and involvement of representatives is important for high vaccine uptake. |
